In CLL-11, for the treatment of first-line patients, in combination with Clb

GAZYVA demonstrated superior PFS vs rituximab product 1

With 6 planned cycles of therapy, GAZYVA (obinutuzumab) delivered a significant improvement in median PFS compared to rituximab product in first-line CLL (26.7 months vs 14.9 months) when each was combined with Clb 1


CLL-11 efficacy results 1

  • GAZYVA + Clb demonstrated a 58% reduction in the risk of CLL progression or death vs rituximab product + Clb (HR=0.42; 95% CI, 0.33-0.54; P<0.0001)